Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
neuroendocrine tumors
market3 mentionslast seen Nov 6, 2026
An application domain being targeted by Perspective Therapeutics' clinical programs.
Relationships 1
Relationship
bamzireotide navoxetanapplies toneuroendocrine tumors
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGARNov 6, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Phase 1/2a clinical trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in patients with unresectable or metastatic somatostatin receptor type 2-expressing neuroendocrine tumors (NETs)
- filingSEC EDGAROct 1, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
VMT-α-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2 for neuroendocrine tumors
- filingSEC EDGARSep 14, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors)